Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer

Patrizia Ferroni; Antonella Spila; Roberta D'Alessandro; Francesca Martini; Francesca Iacovone; Giuseppe M. Ettorre; Giovanni Vennarecci; Roberto Santoro; Claudio Puoti; Fiorella Guadagni

doi:10.1016/j.cca.2010.11.026

Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer

Patrizia Ferroni, Antonella Spila, Roberta D'Alessandro, Francesca Martini, Francesca Iacovone, Giuseppe M. Ettorre, Giovanni Vennarecci, Roberto Santoro, Claudio Puoti, Fiorella Guadagni

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Vascular endothelial growth factor (VEGF₁₆₅) is stored, transported and released by platelets. Platelet functional abnormalities have been described in patients with hepatocellular carcinoma (HCC). Thus, this study was designed to investigate the behavior of VEGF₁₆₅ with respect to platelet activation in HCC. Methods: Plasma and serum VEGF₁₆₅ and plasma sP-selectin levels were analyzed in patients with HCC (n=70) or cirrhosis (n=45) and control subjects (n=70). Given the thrombocytopenia that characterizes both HCC and cirrhotic patients, plasma VEGF₁₆₅ and sP-selectin as well as serum VEGF (plt-VEGF₁₆₅-load) levels were normalized by platelet counts. Results: Median concentrations of plasma VEGF₁₆₅/platelet (p=0.002) and sP-selectin/platelet (p165/platelet at multivariate analysis (p165-load correlated with tumor diameter (p165 release by tumor in HCC. It is plt-VEGF₁₆₅-load, but not plasma VEGF₁₆₅ or serum VEGF₁₆₅ that is an independent predictor for overall survival of HCC patients.

Original language	English
Pages (from-to)	450-454
Number of pages	5
Journal	Clinica Chimica Acta
Volume	412
Issue number	5-6
DOIs	https://doi.org/10.1016/j.cca.2010.11.026
Publication status	Published - Feb 20 2011

Keywords

Angiogenesis
Hepatocellular carcinoma
Platelet activation
Vascular endothelial growth factor

ASJC Scopus subject areas

Biochemistry
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.1016/j.cca.2010.11.026

Fingerprint Dive into the research topics of 'Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer'. Together they form a unique fingerprint.

Cite this

Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer. / Ferroni, Patrizia ; Spila, Antonella; D'Alessandro, Roberta; Martini, Francesca; Iacovone, Francesca; Ettorre, Giuseppe M.; Vennarecci, Giovanni; Santoro, Roberto; Puoti, Claudio; Guadagni, Fiorella.

In: Clinica Chimica Acta, Vol. 412, No. 5-6, 20.02.2011, p. 450-454.

Research output: Contribution to journal › Article › peer-review

Ferroni, Patrizia ; Spila, Antonella ; D'Alessandro, Roberta ; Martini, Francesca ; Iacovone, Francesca ; Ettorre, Giuseppe M. ; Vennarecci, Giovanni ; Santoro, Roberto ; Puoti, Claudio ; Guadagni, Fiorella. / Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 5-6. pp. 450-454.

@article{bcf13783238744e9935d4fd03625d994,

title = "Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer",

abstract = "Background: Vascular endothelial growth factor (VEGF165) is stored, transported and released by platelets. Platelet functional abnormalities have been described in patients with hepatocellular carcinoma (HCC). Thus, this study was designed to investigate the behavior of VEGF165 with respect to platelet activation in HCC. Methods: Plasma and serum VEGF165 and plasma sP-selectin levels were analyzed in patients with HCC (n=70) or cirrhosis (n=45) and control subjects (n=70). Given the thrombocytopenia that characterizes both HCC and cirrhotic patients, plasma VEGF165 and sP-selectin as well as serum VEGF (plt-VEGF165-load) levels were normalized by platelet counts. Results: Median concentrations of plasma VEGF165/platelet (p=0.002) and sP-selectin/platelet (p165/platelet at multivariate analysis (p165-load correlated with tumor diameter (p165 release by tumor in HCC. It is plt-VEGF165-load, but not plasma VEGF165 or serum VEGF165 that is an independent predictor for overall survival of HCC patients.",

keywords = "Angiogenesis, Hepatocellular carcinoma, Platelet activation, Vascular endothelial growth factor",

author = "Patrizia Ferroni and Antonella Spila and Roberta D'Alessandro and Francesca Martini and Francesca Iacovone and Ettorre, {Giuseppe M.} and Giovanni Vennarecci and Roberto Santoro and Claudio Puoti and Fiorella Guadagni",

year = "2011",

month = feb,

day = "20",

doi = "10.1016/j.cca.2010.11.026",

language = "English",

volume = "412",

pages = "450--454",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

number = "5-6",

}

TY - JOUR

T1 - Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer

AU - Ferroni, Patrizia

AU - Spila, Antonella

AU - D'Alessandro, Roberta

AU - Martini, Francesca

AU - Iacovone, Francesca

AU - Ettorre, Giuseppe M.

AU - Vennarecci, Giovanni

AU - Santoro, Roberto

AU - Puoti, Claudio

AU - Guadagni, Fiorella

PY - 2011/2/20

Y1 - 2011/2/20

N2 - Background: Vascular endothelial growth factor (VEGF165) is stored, transported and released by platelets. Platelet functional abnormalities have been described in patients with hepatocellular carcinoma (HCC). Thus, this study was designed to investigate the behavior of VEGF165 with respect to platelet activation in HCC. Methods: Plasma and serum VEGF165 and plasma sP-selectin levels were analyzed in patients with HCC (n=70) or cirrhosis (n=45) and control subjects (n=70). Given the thrombocytopenia that characterizes both HCC and cirrhotic patients, plasma VEGF165 and sP-selectin as well as serum VEGF (plt-VEGF165-load) levels were normalized by platelet counts. Results: Median concentrations of plasma VEGF165/platelet (p=0.002) and sP-selectin/platelet (p165/platelet at multivariate analysis (p165-load correlated with tumor diameter (p165 release by tumor in HCC. It is plt-VEGF165-load, but not plasma VEGF165 or serum VEGF165 that is an independent predictor for overall survival of HCC patients.

AB - Background: Vascular endothelial growth factor (VEGF165) is stored, transported and released by platelets. Platelet functional abnormalities have been described in patients with hepatocellular carcinoma (HCC). Thus, this study was designed to investigate the behavior of VEGF165 with respect to platelet activation in HCC. Methods: Plasma and serum VEGF165 and plasma sP-selectin levels were analyzed in patients with HCC (n=70) or cirrhosis (n=45) and control subjects (n=70). Given the thrombocytopenia that characterizes both HCC and cirrhotic patients, plasma VEGF165 and sP-selectin as well as serum VEGF (plt-VEGF165-load) levels were normalized by platelet counts. Results: Median concentrations of plasma VEGF165/platelet (p=0.002) and sP-selectin/platelet (p165/platelet at multivariate analysis (p165-load correlated with tumor diameter (p165 release by tumor in HCC. It is plt-VEGF165-load, but not plasma VEGF165 or serum VEGF165 that is an independent predictor for overall survival of HCC patients.

KW - Angiogenesis

KW - Hepatocellular carcinoma

KW - Platelet activation

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=78650907073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650907073&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2010.11.026

DO - 10.1016/j.cca.2010.11.026

M3 - Article

C2 - 21111726

AN - SCOPUS:78650907073

VL - 412

SP - 450

EP - 454

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 5-6

ER -